The cell of origin (COO) classification has demonstrated the ability to predict survival outcomes in newly diagnosed diffuse large B-cell lymphoma (DLBCL). However, a study shows that COO loses its prognostic capacity in patients with relapsed/refractory (R/R) DLBCL who undergo chemotherapy followed by autologous stem cell transplantation (auto-SCT). The study appeared in the journal Transplantation and Cellular Therapy.
In this retrospective study, researchers assessed 122 adult patients with R/R DLBCL who underwent auto-SCT at MD Anderson Cancer Center between January 2007 and December 2016. They used the Hans algorithm with CD10, BCL6, and MUM1 markers to classify patients by COO.
According to the results, there were no significant differences in patient characteristics between the two groups, and the median overall survival (OS) time was 68.5 months (95% CI, 51.3 to not reached) for the total population, 68.5 months (95% CI, 44.8 to not reached) for germinal center B-cell GCB, and not reached for non-GCB. Overall, the three-year OS rate was 0.659 (95% CI, 0.575 to 0.755) for the total population, 0.653 (95% CI, 0.547 to 0.779) for GCB, and 0.666 (95% CI, 0.537 to 0.824) for non-GCB. The researchers noted that when adjusted for age and other factors of interest, no statistically significant associations for OS or progression-free survival were observed between both groups.
“Our results confirm that COO loses its prognostic potential in patients with R/R DLBCL who receive high-dose chemotherapy followed by auto-SCT and both GCB and non-GCB types of DLBCL derive similar benefit from auto-SCT,” the researchers concluded. They added that “younger age, female sex, and pretransplantation disease status were associated with better OS.”